Stifel Reiterates Buy Rating on Krystal Biotech (KRYS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as Big Tech earnings rekindle AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
Krystal Biotech's (KRYS) Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301
August 28, 2024 7:01 AM EDTJeune Aesthetics, Inc. (Jeune), a wholly owned subsidiary of Krystal Biotech, Inc. (Krystal) (NASDAQ: KRYS) leveraging Krystals clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today positive interim safety and efficacy results from both Cohorts 3 and 4 of PEARL-1, a Phase 1 study evaluating KB301, an investigational aesthetic treatment designed to deliver the COL3A1 transgene and increase type III... More
